Application of Mycoplasma capricolum subsp. capricepneumonia mccp1801 in preparation of goat infectious pleuropneumoniae vaccine

A technology for pleuropneumonia and mycoplasma, applied in the direction of antibody medical components, bacterial antigen components, medical preparations containing active ingredients, etc., can solve problems such as limited protective effect, inactivation of antigenic epitopes, effective antigen destruction, etc., and achieve growth performance Excellent, early antibody production, improved immune response

Active Publication Date: 2021-09-28
LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the bacteria inactivated vaccines are made from strains that were popular more than ten years ago or earlier. They are inactivated by formaldehyde and other inactivators, and are made with adjuvants such as oil adjuvants. Some sheep have relatively large side effects after immunization. The problem of effective antigen destruction or antigenic epitope inactivation in inactivators such as formaldehyde, as well as the limited protective effect and high cost of virulent Mycoplasma capricosum goat pneumonia subspecies infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Mycoplasma capricolum subsp. capricepneumonia mccp1801 in preparation of goat infectious pleuropneumoniae vaccine
  • Application of Mycoplasma capricolum subsp. capricepneumonia mccp1801 in preparation of goat infectious pleuropneumoniae vaccine
  • Application of Mycoplasma capricolum subsp. capricepneumonia mccp1801 in preparation of goat infectious pleuropneumoniae vaccine

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0027] The method for preparing the inactivated antigen of the present invention preferably comprises: (1) inoculating the recovered Mycoplasma capricoides subsp. The improved MTB culture medium includes components at the following concentrations: 2 g / L of glucose, 2 g / L of sodium pyruvate, 21 g / L of PPLO broth, 100 ml / L of yeast extract with a mass percentage of 25%, and a mass percentage of 1% phenol red 2.5ml / L, horse serum 200ml / L, 100,000 IU penicillin, pH 7.4-7.6;

[0028] (2) centrifuging the mycoplasma bacterium liquid, collecting the bacterium precipitate, and resuspending to obtain a mycoplasma antigen solution with a concentration of 100-400 μg / ml;

[0029] (3) Mix the mycoplasma antigen solution with saponin and inactivate at 4°C for 24-48 hours to obtain the inactivated antigen.

[0030]When the present invention prepares the improved MTB medium described in step (1), it is preferred to dissolve 2 g of glucose and 2 g of sodium pyruvate in 25 ml of water respecti...

Embodiment 1

[0042] Inactivated vaccine preparation

[0043] (1) Preparation of antigen solution

[0044] 1) Medium preparation method: Dissolve 2g of glucose and 2g of sodium pyruvate in 25ml of water respectively, filter and sterilize with a 0.22μm microporous membrane for use; dissolve 21g of PPLO broth in 650ml of deionized water, add 100ml of 25% yeast extract , 2.5ml of 1% phenol red, mixed evenly, sterilized by autoclaving at 121°C for 20min, after cooling, add 200ml of sterile healthy horse serum, 25ml of 8% glucose and 25ml of 8% sodium pyruvate solution sterilized by filtration and 100,000 IU / ml penicillin 1ml, adjust the pH value to 7.4-7.6 with sterilized 1mol / L NaOH, aseptically dispense, store at 4°C for later use, that is, the improved MTB medium.

[0045] 2) Mycoplasma antigen preparation:

[0046] Resuscitate Mycoplasma goati subspecies M1801, inoculate into 4.5ml of improved MTB medium, and culture at 37°C for 24 hours. When the pH value of the culture drops to 6.5-6.8,...

Embodiment 2

[0057] Safety Test of Inactivated Vaccine

[0058]8-9 month old healthy goats (Mccp antibody and antigen negative) were inoculated with the inactivated vaccine of Mycoplasma capricolum subspecies. Each goat was injected with 2 ml of the vaccine in the neck muscles, and the control group was injected with the same amount of PBS for 14 days of continuous observation. Results The goats in the vaccine group and the control group were both healthy and alive, the sheep had no symptoms such as coughing and sneezing, no abnormality in feeding and drinking, and no obvious lumps and other adverse reactions in the injected part, and the vaccine of the present invention was safe.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides the application of Mycoplasma capricosum capreum pneumoniae subspecies Mccp 1801 in the preparation of goat infectious pleuropneumonia vaccine, and relates to the field of biotechnology. The present invention also provides a vaccine based on the M1801 strain and a preparation method thereof. The vaccine can improve the immune protection effect, reduce immune side effects, and provide a good immune protection effect; at the same time, the M1801 strain has strong virulence, good immunogenicity, The growth performance of this strain is excellent. The vaccine of this strain can induce the body to produce high-level antibodies, the antibody production time is early, and the titer is high; the vaccine safety is high; immunity to sheep with 4 / 5 and above protection can significantly reduce body temperature rise, coughing, and sneezing , depression and other symptoms or tissue lesions.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of Mycoplasma capricosum capres pneumoniae subspecies Mccp 1801 in the preparation of goat infectious pleuropneumonia vaccine. Background technique [0002] Contagious caprine pleuropneumonia (CCPP) is a contagious respiratory infectious disease of goats, caused by Mycoplasma capricolum subsp. Fibrinous pleuropneumonia and hepatic changes in the lungs are one of the infectious diseases notifiable by the World Organization for Animal Health (OIE). Goat infectious pleuropneumonia is mainly transmitted by contact and droplets. When the disease breaks out in a new epidemic area, the incidence rate is as high as 100%, and the mortality rate can be as high as 80%. Africa, the Middle East, Asia and other regions are the main epidemic areas of the disease. In recent years, the range of hosts infected by the disease has been increasing, and it has become a serious...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/02A61K39/39A61P31/04
CPCA61K39/0241A61K39/39A61K2039/521A61K2039/55577A61K2039/575A61P31/04
Inventor 储岳峰郝华芳陈胜利颜新敏马丽娜刘永生
Owner LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap